John A. Ward

Array ( [id] => 1600915 [patent_doc_number] => 06475999 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-11-05 [patent_title] => 'Method of inducing an immune response using vaccinia virus recombinants' [patent_app_type] => B1 [patent_app_number] => 09/596716 [patent_app_country] => US [patent_app_date] => 2000-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5010 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/475/06475999.pdf [firstpage_image] =>[orig_patent_app_number] => 09596716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 768214 [patent_doc_number] => 07005126 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-02-28 [patent_title] => 'Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect' [patent_app_type] => utility [patent_app_number] => 09/589255 [patent_app_country] => US [patent_app_date] => 2000-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10006 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/005/07005126.pdf [firstpage_image] =>[orig_patent_app_number] => 09589255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1216717 [patent_doc_number] => 06706694 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-03-16 [patent_title] => 'Expression of exogenous polynucleotide sequences in a vertebrate' [patent_app_type] => B1 [patent_app_number] => 09/588655 [patent_app_country] => US [patent_app_date] => 2000-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 28708 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/706/06706694.pdf [firstpage_image] =>[orig_patent_app_number] => 09588655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 404364 [patent_doc_number] => 07288255 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2007-10-30 [patent_title] => 'Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells' [patent_app_type] => utility [patent_app_number] => 09/568834 [patent_app_country] => US [patent_app_date] => 2000-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10986 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/288/07288255.pdf [firstpage_image] =>[orig_patent_app_number] => 09568834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 993555 [patent_doc_number] => 06916654 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-07-12 [patent_title] => 'Universal donor cells' [patent_app_type] => utility [patent_app_number] => 09/566254 [patent_app_country] => US [patent_app_date] => 2000-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 19287 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/916/06916654.pdf [firstpage_image] =>[orig_patent_app_number] => 09566254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 668704 [patent_doc_number] => 07094946 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-08-22 [patent_title] => 'Animal model for allergic disorders' [patent_app_type] => utility [patent_app_number] => 09/548290 [patent_app_country] => US [patent_app_date] => 2000-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 5934 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/094/07094946.pdf [firstpage_image] =>[orig_patent_app_number] => 09548290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 978562 [patent_doc_number] => 06929792 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-08-16 [patent_title] => 'Modified dendritic cells and use therefor' [patent_app_type] => utility [patent_app_number] => 09/540963 [patent_app_country] => US [patent_app_date] => 2000-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11471 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/929/06929792.pdf [firstpage_image] =>[orig_patent_app_number] => 09540963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1342513 [patent_doc_number] => 06586409 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-07-01 [patent_title] => 'Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines' [patent_app_type] => B1 [patent_app_number] => 09/534943 [patent_app_country] => US [patent_app_date] => 2000-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 27 [patent_no_of_words] => 15565 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/586/06586409.pdf [firstpage_image] =>[orig_patent_app_number] => 09534943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6243070 [patent_doc_number] => 20020045587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-04-18 [patent_title] => 'Delivery of polypeptide-encoding plasmid dna into the cytsol of macrophages by attenuated suicide bacteria' [patent_app_type] => new [patent_app_number] => 09/532964 [patent_app_country] => US [patent_app_date] => 2000-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8490 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0045/20020045587.pdf [firstpage_image] =>[orig_patent_app_number] => 09532964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1228509 [patent_doc_number] => 06696423 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-02-24 [patent_title] => 'Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta' [patent_app_type] => B1 [patent_app_number] => 09/512946 [patent_app_country] => US [patent_app_date] => 2000-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 18065 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/696/06696423.pdf [firstpage_image] =>[orig_patent_app_number] => 09512946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 483633 [patent_doc_number] => 07220826 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2007-05-22 [patent_title] => 'Expressing gp140 fragment of primary HIV-1 isolate' [patent_app_type] => utility [patent_app_number] => 09/914205 [patent_app_country] => US [patent_app_date] => 2000-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 14 [patent_no_of_words] => 5082 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/220/07220826.pdf [firstpage_image] =>[orig_patent_app_number] => 09914205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1576737 [patent_doc_number] => 06447767 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-09-10 [patent_title] => 'Non-myeloablative tolerogenic treatment' [patent_app_type] => B1 [patent_app_number] => 09/506082 [patent_app_country] => US [patent_app_date] => 2000-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 30953 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/447/06447767.pdf [firstpage_image] =>[orig_patent_app_number] => 09506082 [rel_patent_id] =>[rel_patent_doc_number] =>)